US Patent

US11951214 — Capsule formulations

Formulation · Assigned to Chemocentryx Inc · Expires 2039-11-27 · 14y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects solid solution capsule formulations of Compound 1 and methods for making and using them to treat diseases involving C5a receptors.

USPTO Abstract

The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.

Drugs covered by this patent

Patent Metadata

Patent number
US11951214
Jurisdiction
US
Classification
Formulation
Expires
2039-11-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Chemocentryx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.